Clinical trials · Minnesota
B Cell Malignancies clinical trials in Minnesota
We’re tracking 31 recruiting b cell malignancies studies with a site in Minnesota — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Brainerd, MinnesotaAges 18 years+ - NCT05006716RecruitingPhase 1/Phase 2
Testing a new drug for certain B-cell blood cancers
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
Rochester, MinnesotaAges 18 years+ - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Rochester, MinnesotaAges 13–90 - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Aitkin, MinnesotaAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Rochester, MinnesotaAges 18 years+ - NCT06542250RecruitingPhase 1/Phase 2
Study of a new immune therapy for relapsed B-cell cancers
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT04892277RecruitingPhase 1
CD19 CAR-T for adults with hard-to-treat B-cell cancers
This Phase 1 trial tests a lab-made immune therapy (CD19 CAR-T) for adults whose B-cell cancers have come back or did not respond to treatment. It may help your immune system better recognize and attack cancer cells, but it is early research, so benefits and risks are still being defined.
Rochester, MinnesotaAges 18 years+ - NCT04792489RecruitingPhase 2
CAR-T cell therapy for aggressive B-cell lymphomas
This trial tests a new CAR-T cell treatment (MB-CART2019.1) for people with certain types of aggressive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to prior treatments. It aims to see if this therapy can help when other options have failed.
Rochester, MinnesotaAges 18 years+ - NCT05890352RecruitingPhase 2
Add new medicines to standard treatment for returning lymphoma
This Phase 2 study tests whether adding tafasitamab, lenalidomide, tazemetostat, and zanubrutinib (along with standard lymphoma treatment) can improve outcomes in people whose large B-cell lymphoma has returned or not responded. It may help control disease more effectively and improve response duration for eligible patients.
Virginia, MinnesotaAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Rochester, MinnesotaAges 18 years+ - NCT06536049RecruitingPhase 1/Phase 2
Epcoritamab plus ibrutinib for relapsed or refractory aggressive B-cell lymphoma
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
Minneapolis, MinnesotaAges 18 years+ - NCT06634589RecruitingPhase 1/Phase 2
Study of a new drug combo for returning B-cell blood cancers
This trial tests a new drug combination for people with B-cell blood cancers (like lymphoma or leukemia) that have returned or stopped responding to treatment. It aims to find out if the combination is safe and works better than current options.
Rochester, MinnesotaAges 18 years+ - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Mankato, MinnesotaAges 18 years+ - NCT07271667RecruitingPhase 2
Study of emavusertib with zanubrutinib for CLL and other B-cell cancers
This trial combines an experimental drug, emavusertib, with zanubrutinib (a standard targeted therapy) for people with chronic lymphocytic leukemia (CLL) or other B-cell cancers. It aims to see if the combination can improve response in patients who still have some disease despite taking zanubrutinib or whose disease has worsened on it.
Rochester, MinnesotaAges 18 years+ - NCT06462365RecruitingPhase 1
Preventing GvHD after stem cell transplant for blood cancers
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Minneapolis, MinnesotaAges 18 years+ - NCT03666000RecruitingPhase 1
Testing a CD19 CAR T cell treatment for relapsed blood cancers
This Phase 1 study tests the safety and best dose of a CD19 CAR T cell therapy (azer-cel) in people whose B-cell blood cancer has returned or did not respond to treatment. It may help people with relapsed/refractory B-ALL or certain aggressive or large B-cell lymphomas, including after or before prior CAR T treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT06151730Recruiting
Managing blood pressure and heart risks during BTKi treatment
This study looks at how well blood pressure is managed and whether heart problems can be prevented in people with certain blood cancers who are taking a type of targeted therapy called a BTKi. It aims to help you stay healthier during treatment.
Rochester, MinnesotaAges Any age - NCT06091865RecruitingPhase 3
Testing odronextamab with chemo for untreated DLBCL
This trial is testing a new drug called odronextamab combined with chemotherapy against the standard treatment for people with previously untreated DLBCL. The goal is to see if the new combination works better and is safe.
Rochester, MinnesotaAges 18 years+ - NCT07123454RecruitingPhase 1/Phase 2
Study of AZD4512 for relapsed or refractory B-cell lymphoma
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
Rochester, MinnesotaAges 18 years+ - NCT03314974RecruitingPhase 2
Stem cell transplant study for blood cancers
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT06890884RecruitingPhase 2
Comparing two drug combos for untreated DLBCL
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Burnsville, MinnesotaAges 18 years+ - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Minneapolis, MinnesotaAges 18 years+ - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Minneapolis, MinnesotaAges 1–21
Where these studies are running in Minnesota
Institutions with a site for the recruiting b cell malignancies studies listed above.
- Mayo Clinic · 13 studies
- Essentia Health - Deer River Clinic · 3 studies
- Essentia Health Cancer Center · 3 studies
- Essentia Health Hibbing Clinic · 3 studies
- Essentia Health Sandstone · 3 studies
- Essentia Health Virginia Clinic · 3 studies
- Essentia Health Saint Joseph's Medical Center · 2 studies
- Research Site · 2 studies
What taking part in a b cell malignancies study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
B Cell Malignancies trials in other states
Common questions
- Are there b cell malignancies clinical trials in Minnesota?
- Yes. We're currently tracking 31 recruiting b cell malignancies studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a b cell malignancies study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a b cell malignancies trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New b cell malignancies studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.